(PharmaNewsWire.Com, February 20, 2018 ) The Middle East and Africa Chlamydia Infection Diagnostics and Therapeutics market size was around USD 60 million in 2017. It is expected to grow at a CAGR of 5.3% to reach USD 80 million by 2022. It captures 3% of the global market share.Chlamydia is a sexually transmitted disease. The symptoms do not occur early on. It is usually prevalent in areas with poor sanitation. It is the most common STD worldwide. Number of victims has been increasing over the last decade.
Increasing number of cases of these diseases better and complete reporting in emerging economies, augmenting screening coverage, improved funding for better R&D in this area, growing awareness regarding STDs in the developing countries along with the increased healthcare expenditures are the factors driving the growth of this market. Also accessibility to and availability of hyper sensitive diagnostic tests are also boosting the growth of this market. Furthermore, improved insurance coverage in the emerging economies augurs well for this market.However, the stigma associated with sexually transmitted diseases is the primary restraint of market growth.
This market is broadly segmented by product type and end user into diagnostics and therapeutics segments. Classification in diagnostics by product type entails Nucleic Acid Amplification Tests (NAATs), Direct Fluorescent Tests, and PCR. NAAT accounted for the largest market share in 2016 and is predicted to grow robustly in the forecast period. It is closely tailed by DFT in terms of CAGR. This is because NAATs are more sensitive and diagnose better. Classification in diagnostics by end user entails Hospitals, Specialty Clinics, and Diagnostic Centres.
Classification in therapeutics by product type entails Macrolides, Quinolones, Sulphonamides, Tetracycline, and Aminopenicillins. Macrolides is expected to undergo high growth in the forecast period. It also captures the largest market share and is expected to stay at the top in the forecast period. Classification in therapeutics by end user entails Hospital Pharmacies, Drugstores, Retail Pharmacies, and Online Pharmacies.
Classification by geography entails Middle East and Africa. It is the least attractive market.
Key players in the market include Bio Rad laboratories, Novartis AG, F Hoffmann-La Roche, Abbott Laboratories, Danaher. Other players in the market include bioMerieux, DiaSorin SpA, Siemens AG, Thermo Fisher Scientific, and Becton Dickinson and Company.
Scope of the report
The report offers a comprehensive analysis of the industry by providing the estimations of market potential and forecasts with utmost granularity. Along this, the factors influential in effecting the market dynamics and trends are discussed in detail at the product level. Further, the performance of the market at the regional and country-level is assessed and the prospects with high growth potential are identified and debated.
The key players in the industry are profiled providing insights on their financial performance, market position and growth strategies. Comparative analysis on prime strategical activities of the market players delineating the key developments like mergers & acquisitions, collaborations and an evaluation of the competitive environment within the industry are provided. The report also offers a broad outlook of the market along with recommendations from industry experts on the opportunities for investment activity.
What else? Apart from the syndicated report, our in-house team has an expertise and experience in designing custom reports to meet your specific research needs and assist you in making well-informed decisions.
About MarketDataForecast™-
Market Data Forecast is a market research firm offering syndicated research, consults and industry newsletters across various domains & verticals. With a well-established in-house team of experts from diverse fields and outsource research network across 100+ countries, we are the sole research providers for the majority of Fortune 500 companies. Along with the standards of reports being on par excellence, our unique services like free customization, analyst support for the period of six months post to the purchase will be the flag bearers and differentiates us from the rest. Our experience and in-depth understanding of various business environments will be a support to you and your organization in making well-informed decisions.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
